Subscribe: Merck.com - Financial News
http://www.merck.com/rss/financial.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
business wire  english contact  gaap eps  kenilworth  language english  merck  mrk  nyse  quarter  slug ticker  ticker  united states 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Merck.com - Financial News

Financial News





 



Merck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25

Fri, 23 Sep 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 25. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Host Investor Teleconference to Discuss ESMO 2016 Highlights

Tue, 20 Sep 2016 12:30:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will host a teleconference for investors following the presentation of data at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 – 11. The call will take place on Sunday, Oct. 9 at 6:30 p.m. CEST (12:30 p.m. EDT). Company executives will provide an overview of data presented and address questions.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Kim Hamilton, 908-740-1863
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Participate at the Morgan Stanley Global Healthcare Conference

Fri, 09 Sep 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories, are scheduled to participate at the Morgan Stanley Global Healthcare Conference in New York on Sept. 12, 2016 at 1:05 p.m. EDT.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Second-Quarter 2016 Financial Results

Fri, 29 Jul 2016 10:45:00 +0000

Dateline City:
KENILWORTH, N.J.
  • Second-Quarter 2016 Worldwide Sales Were $9.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange
  • Second-Quarter 2016 GAAP EPS Was $0.43; Second-Quarter Non-GAAP EPS Was $0.93
  • Company Updates EPS Guidance: Full-Year 2016 GAAP EPS Range to be Between $1.98 and $2.08; Full-Year 2016 Non-GAAP EPS Range of $3.67 to $3.77
  • Advanced KEYTRUDA Development Program
    • KEYTRUDA Demonstrated Superior Progression-Free Survival and Overall Survival Compared to Chemotherapy in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Expressed PD-L1 in KEYNOTE-024 Study
    • Merck Received Positive Opinion from Committee for Medicinal Products for Human Use of the European Medicines Agency for KEYTRUDA for the Treatment of Previously Treated Advanced NSCLC in Patients Whose Tumors Express PD-L1

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2016.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Fourth-Quarter 2016 Dividend

Tue, 26 Jul 2016 16:50:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the fourth quarter of 2016. Payment will be made on Oct. 7, 2016 to shareholders of record at the close of business on Sept. 15, 2016.

About Merck

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29

Fri, 24 Jun 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Friday, July 29. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Acquire Afferent Pharmaceuticals

Thu, 09 Jun 2016 21:07:00 +0000

Dateline City:
KENILWORTH, N.J. & SAN MATEO, Calif.

KENILWORTH, N.J. & SAN MATEO, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed, neurogenic conditions.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Michael Close, 267-305-1211
or
Investors:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879
or
Afferent
Media:
Susan Kinkead, 415-509-3610
or
Investors:
Dulce Dizon, 650-286-1276

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Hold Investor Briefing at 2016 ASCO Annual Meeting

Wed, 01 Jun 2016 21:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Dr. Roger M. Perlmutter, president, Merck Research Laboratories, will present an overview of the company’s oncology program at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on June 6, 2016 at 5:45 p.m. CDT (6:45 p.m. EDT).

Language:
English
Contact:

Merck
Media:
Lainie Keller, (908) 236-5036
or
Investor:
Teri Loxam, (908) 740-1986
or
Justin Holko, (908) 740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Third-Quarter 2016 Dividend

Tue, 24 May 2016 18:35:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the third quarter of 2016. Payment will be made on July 8, 2016 to shareholders of record at the close of business on June 15, 2016.

About Merck

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Present at the UBS Global Healthcare Conference

Tue, 24 May 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Adam Schechter, executive vice president and president, Global Human Health, Merck, is scheduled to present at the UBS Global Healthcare Conference in New York on May 25, 2016 at 8:00 a.m. EDT.

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://investors.merck.com/investors/webcasts-and-presentations/default.aspx.

Language:
English
Contact:

Media:
Lainie Keller, (908) 236-5036
or
Investor:
Teri Loxam, (908) 740-1986
Justin Holko, (908) 740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces First-Quarter 2016 Financial Results

Thu, 05 May 2016 10:45:00 +0000

Dateline City:
KENILWORTH, N.J.
  • First-Quarter 2016 GAAP EPS was $0.40; First-Quarter Non-GAAP EPS Increased by 5 Percent to $0.89
  • Company Continues to Expect 2016 Full-Year GAAP EPS to be Between $1.96 and $2.23; Narrows and Raises 2016 Full-Year Non-GAAP EPS to be Between $3.65 and $3.77
  • First-Quarter 2016 Worldwide Sales Were $9.3 Billion, a Decrease of 1 Percent, Including a 4 Percent Negative Impact from Foreign Exchange
  • Obtained FDA Approval of ZEPATIER in the Treatment of Chronic Hepatitis C Genotypes 1 or 4 Infection
  • Advanced KEYTRUDA Development Program
    • sBLA Accepted for Recurrent or Metastatic Head and Neck Cancer
    • Breakthrough Therapy Designation Granted for Classical Hodgkin Lymphoma

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2016.

“Our first quarter’s performance sets us on a good course for the year,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “We remain focused on advancing our pipeline and driving the commercial success of our key launches and inline medicines and vaccines.”

Financial Summary

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Present at the Deutsche Bank 41st Annual Health Care Conference

Wed, 04 May 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Adam Schechter, executive vice president and president, Global Human Health, Merck, is scheduled to present at the Deutsche Bank 41st Annual Health Care Conference in Boston on May 5, 2016 at 12:50 p.m. EDT.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
Steven Cragle, 908-740-1801
or
Investors:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Hold First-Quarter 2016 Sales and Earnings Conference Call on May 5

Fri, 08 Apr 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Thursday, May 5. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
Claire Gillespie, 267-305-0932
or
Investors:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Second-Quarter 2016 Dividend

Tue, 23 Feb 2016 18:30:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the second quarter of 2016. Payment will be made on April 7, 2016, to shareholders of record at the close of business on March 15, 2016.

About Merck

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results

Wed, 03 Feb 2016 11:45:00 +0000

Dateline City: KENILWORTH, N.J. Fourth-Quarter 2015 GAAP EPS was $0.35; Fourth-Quarter Non-GAAP EPS was $0.93, an Increase of 7 Percent; Full-Year 2015 GAAP EPS was $1.56; Full-Year 2015 Non-GAAP EPS was $3.59, an Increase of 3 Percent Fourth-Quarter 2015 Worldwide Sales Were $10.2 Billion, a Decrease of 3 Percent, Including a 7 Percent Negative Impact from Foreign Exchange and 3 Percent Net Favorable Impact from Acquisitions and Divestitures Full-Year 2015 Worldwide Sales Were $39.5 Billion, a Decrease of 6 Percent, Reflecting a 6 Percent Negative Impact from Foreign Exchange and a 3 Percent Net Unfavorable Impact from Acquisitions and Divestitures 2016 Financial Outlook Expects Full-Year 2016 GAAP EPS to be Between $1.96 and $2.23; Expects Non-GAAP EPS to be Between $3.60 and $3.75, Including an Approximately 4 Percent Negative Impact from Foreign ExchangeAnticipates Full-Year 2016 Worldwide Sales to be Between $38.7 Billion and $40.2 Billion, Including an Approximately 3 Percent Negative Impact from Foreign Exchange Advanced KEYTRUDA ProgramsBLA Approval for Treatment of Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1Expanded Indication for First-Line Treatment of Patients with Unresectable or Metastatic Melanoma Obtained FDA Approval of ZEPATIER in the Treatment of Chronic Hepatitis C KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2015. “The past year was one of considerable progress and execution for Merck,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “I’m excited by the near-term opportunities, as we continue launching important new products like ZEPATIER and KEYTRUDA while augmenting and advancing our pipeline.” Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steven Cragle, 908-740-1801orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more[...]



Merck Announces Increased Quarterly Dividend

Tue, 24 Nov 2015 17:35:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the company’s quarterly dividend to $0.46 per outstanding share of the company’s common stock, up $0.01 from $0.45 per outstanding share paid last quarter. Payment will be made on Jan. 8, 2016, to stockholders of record at the close of business on Dec. 15, 2015.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Third-Quarter 2015 Financial Results

Tue, 27 Oct 2015 10:45:00 +0000

Dateline City:
KENILWORTH, N.J.
  • Increased Non-GAAP EPS by 7 Percent to $0.96; GAAP EPS of $0.64
  • Raised 2015 Full-Year Non-GAAP EPS Target to a Range of $3.55 – $3.60 and GAAP EPS Target to a Range of $1.64 – $1.74
  • Worldwide Sales Were $10.1 Billion, a Decrease of 5 Percent; Excluding the Impact of Foreign Exchange, Acquisitions and Divestitures, Worldwide Sales Grew 4 Percent
  • Advanced KEYTRUDA Program
    • FDA Approved sBLA for the Treatment of Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
    • In KEYNOTE-010 Study KEYTRUDA Showed Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced NSCLC Whose Tumors Express PD-L1
    • Third-Quarter Sales Were Approximately $160 million

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2015.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
Steven Cragle, 908-740-1801
or
Investors:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1789

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Hold Third-Quarter 2015 Sales and Earnings Conference Call on October 27

Fri, 25 Sep 2015 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 27. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Language:
English
Contact:

Merck & Co., Inc.
Media:
Lainie Keller, 908-236-5036
Steven Cragle, 908-740-1801
or
Investors:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Second-Quarter 2015 Financial Results

Tue, 28 Jul 2015 11:00:00 +0000

Dateline City:
KENILWORTH, N.J.
  • Second-Quarter 2015 Non-GAAP EPS of $0.86, Excluding Certain Items; GAAP EPS of $0.24
  • Company Narrows and Raises 2015 Full-Year Non-GAAP EPS Target to $3.45 to $3.55, Excluding Certain Items; Lowers 2015 Full-Year GAAP EPS Target to $1.52 to $1.71
  • Second-Quarter 2015 Worldwide Sales Were $9.8 Billion, a Decrease of 11 Percent, Including a 7 Percent Net Unfavorable Impact from Acquisitions and Divestitures and a 7 Percent Negative Impact from Foreign Exchange
  • Second-Quarter Results Reflect Sales Growth in Hospital Acute Care, Oncology and Diabetes and Sales Declines in Cardiovascular and Hepatitis C
  • European Commission Approved KEYTRUDA for the Treatment of Advanced Melanoma; FDA Accepted sBLA for KEYTRUDA in Advanced Non-Small Cell Lung Cancer
  • Grazoprevir/Elbasvir Chronic Hepatitis C Combination Regimen Accepted for Regulatory Review in Both the United States and European Union

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2015.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
Steven Cragle, 908-740-1801
or
Investors:
Justin Holko, 908-740-1879
Joe Romanelli, 908-740-1986

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Fourth-Quarter 2015 Dividend

Wed, 22 Jul 2015 17:28:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.45 per share of the company’s common stock for the fourth quarter of 2015. Payment will be made on October 7, 2015, to shareholders of record at the close of business on September 15, 2015.

About Merck

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investor:
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28

Fri, 26 Jun 2015 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, July 28. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or Steven Cragle, 908-740-1801
or
Investor:
Justin Holko, 908-740-1879
or Joe Romanelli, 908-740-1986

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Third-Quarter 2015 Dividend

Tue, 26 May 2015 17:31:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.45 per share of the company’s common stock for the third quarter of 2015. Payment will be made on July 8, 2015, to stockholders of record at the close of business on June 15, 2015.

About Merck

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces First-Quarter 2015 Financial Results

Tue, 28 Apr 2015 11:00:00 +0000

Dateline City: KENILWORTH, N.J. First-Quarter 2015 Non-GAAP EPS of $0.85, Excluding Certain Items; GAAP EPS of $0.33 Company Narrows and Raises 2015 Full-Year Non-GAAP EPS Target to $3.35 to $3.48, Excluding Certain Items; Lowers 2015 Full-Year GAAP EPS Target to $1.58 to $1.85 First-Quarter 2015 Worldwide Sales Were $9.4 Billion, a Decrease of 8 Percent, Reflecting Net Unfavorable Impact of Acquisitions and Divestitures and a 5 Percent Negative Impact from Foreign Exchange First-Quarter Results Reflect Sales Growth in Diabetes, Vaccines, Hospital Acute Care, Oncology and Animal Health and Sales Decline in Hepatitis C Company Submitted sBLA for KEYTRUDA for Advanced Non-Small Cell Lung Cancer and Expects to Submit sBLA for First-Line Indication in Advanced Melanoma in Mid-2015 Multiple Data Sets Evaluating Chronic Hepatitis C Combination Regimen Grazoprevir/Elbasvir Were Presented at EASL; Company Reiterated Plans for NDA Submission in the First Half of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2015. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steven Cragle, 908-740-1801orInvestors:Justin Holko, 908-740-1879Joe Romanelli, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more[...]



Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28

Fri, 27 Mar 2015 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2015 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, April 28. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Language:
English
Contact:

Merck
Media:
Lainie Keller, (908) 236-5036
Steven Cragle, (908) 740-1801
or
Investor:
Justin Holko, (908) 740-1879
Joe Romanelli, (908) 740-1986

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces New $10 Billion Share Repurchase Program

Tue, 24 Mar 2015 21:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that its board of directors has authorized additional purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or Steve Cragle, 908-740-1801
or
Investor:
Joseph Romanelli, 908-740-1986
or Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more